The findings demonstrated that CPT2 expression was significantly lower in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), head-neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), LIHC, lung squamous cell carcinoma (LUSC) and rectal adenocarcinoma (READ) (Figure 3C). This evidence concerns the gene CPT2 and cholangiocarcinoma.